Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: A meta-analysis

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Ni, Wentao ^a   Shao, Xiaodi ^a   Cai, Xuejiu ^a   Wei, Chuanqi ^a   Cui, Junchang ^a   Wang, Rui ^a   Liu, Youning ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; PLACEBO; MACROLIDE;

ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE; ANTIBIOTIC THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; GASTROINTESTINAL SYMPTOM; HOSPITALIZATION; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; COMPLICATION; DISEASE COURSE; INFLAMMATION; ODDS RATIO; PUBLISHING; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS);

ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; MACROLIDES; ODDS RATIO; PUBLICATION BIAS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84926381750     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121257     Document Type: Article

References (39)

1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007; 370: 765-773. PMID: 17765526
2. World Health Organization. Chronic obstructive pulmonary disease. Available: http://www.who.int/respiratory/copd/en/.
3. Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J. 2013; 42: 239-251. doi: 10.1183/09031936.00136712 PMID: 23180583
4. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67: 957-963. doi: 10.1136/thoraxjnl-2011-201518 PMID: 22684094
5. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23: 932-946. PMID: 15219010
6. Marchetti N, Criner GJ, Albert RK. Preventing acute exacerbations and hospital admissions in COPD. Chest. 2013; 143: 1444-1454. doi: 10.1378/chest.12-1801 PMID: 23648908
7. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011; 65: 1184-1192.
8. Sethi S, Murphy T F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008; 359: 2355-2365. doi: 10.1056/NEJMra0800353 PMID: 19038881
9. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflmmation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006; 173: 1114-1121. PMID: 16484677
10. Donath E, Chaudhry A, Hernandez-Aya LF, Lit L. A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmonary Disease. Respir Med. 2013; 107:1385-1392. doi: 10.1016/j.rmed.2013.05.004 PMID: 23768735
11. Yao GY, Ma YL, Zhang MQ, Gao ZC. Macrolide therapy decreases chronic obstructive pulmonary disease exacerbation: a meta-analysis. Respiration. 2013; 86: 254-260. doi: 10.1159/000350828 PMID: 23817204
12. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. Available: http://www.goldcopd.org/.
13. Suzuki T, Yanai M, Yamaya M, Satoh-Nakagawa T, Sekizawa K, Ishida S, et al. Erythromycin and common cold in COPD. Chest. 2001; 120: 730-733. PMID: 11555501
14. Banerjee D, Khair OA, Honeybourne D. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med. 2005; 99: 208-215. PMID: 15715188
15. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008; 178: 1139-1147. doi: 10.1164/rccm.200801-145OC PMID: 18723437
16. Blasi F, Bonardi D, Aliberti S, Tarsia P, Confalonieri M, Amir O, et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther. 2010; 23: 200-207. doi: 10.1016/j.pupt.2009.12.002 PMID: 20025989
17. He ZY, Ou LM, Zhang JQ, Bai J, Liu GN, Li MH, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration. 2010; 80: 445-452. doi: 10.1159/000321374 PMID: 20881376
18. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011; 365: 689-698. doi: 10.1056/NEJMoa1104623 PMID: 21864166
19. Berkhof FF, Doornewaard-ten Hertog NE, Uil SM, Kerstjens HA, Van den Berg JW. Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respir Res. 2013; 14: 125. doi: 10.1186/1465-9921-14-125 PMID: 24229360
20. Simpson JL, Powell H, Baines KJ, Milne D, Coxson HO, Hansbro PM, et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLoS One. 2014; 9: e105609. doi: 10.1371/journal.pone.0105609 PMID: 25148049
21. Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014; 2: 361-368. doi: 10.1016/S2213-2600(14)70019-0 PMID: 24746000
22. Mazzei T, Mini E, Novelli A, Periti P. Chemistry and mode of action of macrolides. J Antimicrob Chemother. 1993; 31: 1-9. PMID: 8396080
23. Bearden DT, Rodvold KA. Penetration of macrolides into pulmonary sites of infection.Infect Med. 1999; 16: 480-484.
24. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Guidelines for the management of adult lower respiratory tract infections - full version. Clin Microbiol Infect. 2011; 17: E1-E59. doi: 10.1111/j.1469-0691.2011.03672.x PMID: 21951385
25. Yamaya M, Azuma A, Takizawa H, Kadota J, Tamaoki J, Kudoh S. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J. 2012; 40: 485-494. doi: 10.1183/09031936.00208011 PMID: 22408201
26. Florescu DF, Murphy PJ, Kalil AC. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. Pulm Pharmacol Ther. 2009; 22: 467-472. doi: 10.1016/j.pupt.2009.03.002 PMID: 19328860
27. Figueiredo Bde C, Ibiapina Cda C. The role of macrolides in noncystic fibrosis bronchiectasis. Pulm Med. 2011; 2011: 751982. doi: 10.1155/2011/751982 PMID: 22292118
28. Herath SC, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2013; 11: CD009764. doi: 10.1002/14651858.CD009764.pub2 PMID: 24288145
29. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term effects of azithromycin in patients with cystic firosis: a double blind, placebo controlled trial. Thorax. 2006; 61: 895-902. PMID: 16809416
30. Gómez J, Baños V, Simarro E, Lorenzo Cruz M, Ruiz Gómez J, Latour J, et al. Prospective comparative study (1994-1998) of the influence of short-term prophylactic treatment with azithromycin on patients with advanced COPD. Rev Esp Quimioter. 2000; 13: 379-383. PMID: 11498704
31. Rabe KF, Fabbri LM, Vogelmeier C, Kögler H, Schmidt H, Beeh KM, et al. Seasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trial. Chest. 2013; 143: 711-719. PMID: 23188489
32. Cameron EJ, McSharry C, Chaudhuri R, Farrow S, Thomson NC. Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. Clin Exp Allergy. 2012; 42: 1302-1312. doi: 10.1111/j.1365-2222.2012.03979.x PMID: 22925316
33. Rubin BK. Immunomodulatory properties of macrolides: overview and historical perspective. Am J Med. 2004; 117: Suppl 9A, 2-4.
34. Marjanović N, Bosnar M, Michielin F, Willé DR, Anić-Milić T, Culić O, et al. Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. Pharmacol Res. 2011; 63: 389-397. doi: 10.1016/j.phrs.2011.02.001 PMID: 21315154
35. Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014; 189: 1503-1508. doi: 10.1164/rccm.201402-0207OC PMID: 24779680
36. Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD. Arch Bronconeumol. 2012; 48: 247e57. doi: 10.1016/j.arbres.2012.04.001 PMID: 22561012
37. Schembri S, Williamson PA, Short PM, Singanayagam A, Akram A, Taylor J, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ. 2013; 346: f1235. doi: 10.1136/bmj.f1235 PMID: 23525864
38. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004; 351: 1089-1096. PMID: 15356306
39. Wayne RA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012; 366: 1881-1890. doi: 10.1056/NEJMoa1003833 PMID: 22591294